Halozyme Therapeutics Inc (HALO)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	557,132	480,093	416,706	392,119	348,329	317,945	289,892	226,747	248,918	232,937	233,336	294,841	248,518	266,957	229,121	163,480	129,302	21,593	-39,679	-80,161
Revenue (ttm)	US$ in thousands	1,015,324	947,355	873,304	862,989	829,253	780,710	773,653	704,980	660,116	580,623	487,477	471,567	443,310	463,010	412,496	331,262	267,594	199,556	180,470	164,397
Pretax margin		54.87%	50.68%	47.72%	45.44%	42.01%	40.73%	37.47%	32.16%	37.71%	40.12%	47.87%	62.52%	56.06%	57.66%	55.55%	49.35%	48.32%	10.82%	-21.99%	-48.76%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $557,132K ÷ $1,015,324K
= 54.87%

Halozyme Therapeutics Inc's pretax margin has shown fluctuating trends over the provided periods, ranging from negative values to positive percentages. The margin experienced significant improvement from negative figures in March 2020 and June 2020 to a positive pretax margin of 10.82% in September 2020. Subsequently, there was a substantial increase in profitability, reaching a high of 62.52% in March 2022. The company sustained this positive momentum, with pretax margins peaking at 57.66% in September 2021. However, there was a slight decrease in margins in the following quarters, hovering around 40%-50%. The pretax margin showed an upward trend again, reaching 54.87% in December 2024. Overall, the company has demonstrated an ability to improve profitability over time, with fluctuations reflecting changing market conditions and financial performance.